Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer

被引:221
作者
Wang, PC
Yang, KY
Chao, JY
Liu, JM
Perng, RP
Yen, SH
机构
[1] Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Ctr Canc, Taipei, Taiwan
[3] Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan
关键词
cardiac tamponade; cytology; lung cancer; malignant pericardial effusion; treatment;
D O I
10.1378/chest.118.3.744
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background and study objectives: Cardiac tamponade is a life-threatening complication of non-small cell lung cancer (NSCLC). Malignant pericardial effusion signifies advanced disease, but the significance of a negative pericardial fluid cytology in patients with advanced lung cancer is still controversial, The differential diagnosis of cytology-negative pericardial effusion is difficult and sometimes impossible. The purpose of this study is to determine the prognostic role of pericardial fluid cytology in patients with NSCLC and cardiac tamponade, Design: Retrospective review of patients with concurrent NSCLC and cardiac tamponade over a 10-year period. Methods and results: Eighty-two patients mere included in this study. Pericardial fluid cytology was positive in 60 patients and negative in 22 patients. The overall median survival was 74.5 days, and 1-year survival was 7.3%, with no survival difference between the two groups (p = 0.2506), However, there was a significant survival difference after different treatment strategies. Patients receiving systemic chemotherapy survived longer than those receiving local therapy (p < 0.001), and these patients, in turn, survived longer than those receiving supportive treatment (p < 0.001). Conclusions: When patients have concur-rent advanced NSCLC and cardiac tamponade, the most likely cause of the pericardial effusion is the cancer itself, regardless of the results of the cytologic examination, Our results suggest that systemic chemotherapy might prolong survival in such patients, but further prospective, randomized study is necessary.
引用
收藏
页码:744 / 749
页数:6
相关论文
共 49 条
[1]   CARDIOVASCULAR SEQUELAE OF THERAPEUTIC THORACIC RADIATION [J].
ARSENIAN, MA .
PROGRESS IN CARDIOVASCULAR DISEASES, 1991, 33 (05) :299-312
[2]   INCIDENCE AND CLINICAL MANIFESTATIONS OF CARDIAC METASTASES [J].
BISEL, HF ;
LADUE, JS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1953, 153 (08) :712-715
[3]   THE SIGNIFICANCE OF PLEURAL EFFUSION COMPLICATING OTHERWISE OPERABLE BRONCHOGENIC CARCINOMA [J].
BRINKMAN, GL .
DISEASES OF THE CHEST, 1959, 36 (02) :152-154
[4]  
BUCK M, 1987, CANCER, V60, P263, DOI 10.1002/1097-0142(19870715)60:2<263::AID-CNCR2820600225>3.0.CO
[5]  
2-N
[6]  
BUDINGER JM, 1958, CANCER, V11, P106, DOI 10.1002/1097-0142(195801/02)11:1<106::AID-CNCR2820110121>3.0.CO
[7]  
2-9
[8]  
BUZAID AC, 1989, WESTERN J MED, V150, P174
[9]   CARCINOMATOUS INVOLVEMENT OF PLEURA - ANALYSIS OF 96 PATIENTS [J].
CHERNOW, B ;
SAHN, SA .
AMERICAN JOURNAL OF MEDICINE, 1977, 63 (05) :695-702
[10]   HEART DISEASE FOLLOWING RADIATION [J].
COHN, KE ;
STEWART, JR ;
FAJARDO, LF ;
HANCOCK, EW .
MEDICINE, 1967, 46 (03) :281-&